Pivotal Life Sciences, a global investment firm dedicated to investing in companies involved in healthcare innovation seeking to improve patient outcomes, closed Pivotal bioVenture Partners Fund II, at $389m.
Fund II will continue Pivotal bioVenture Partners’ core strategy of investing in companies based in North America and Europe developing innovative and impactful therapeutics.
Led by Rob Hopfner, Managing General Partner, and Peter Bisgaard, Managing Director, Pivotal Life Sciences invests in companies at all stages from seed stage to publicly listed, with a preference for leading or co-leading investments and working alongside entrepreneurs as company builders and active board members.
Pivotal has built a team of technology industry engineers focused on creating tools designed to optimize deal sourcing, deal selection, due diligence, and portfolio management for its investment team as well as support resources for management teams in portfolio companies that it plans to employ in Fund II. The establishment of Fund II will enable Pivotal to continue to talent to guide and grow these companies in key healthcare and therapeutic areas.
The closing brings Pivotal bioVenture Partners’ total aggregate capital commitments to $689 million. The portfolio includes Karuna, Vaxcyte, Evommune, Maplight Therapeutics, etc.
Pivotal Life Sciences is based in San Francisco, CA Cambridge, MA, Shangai, China, and Hong Kong.